Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER + HER2 − Breast Cancer
Cell Proliferation · 2026
DOI: 10.1111/cpr.70100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2026. Verfasst von Liqin Ping und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endocrine resistance is a leading cause of mortality in oestrogen receptor‐positive and human epidermal growth factor receptor 2‐negative (ER+HER2−) breast cancer (BC), highlighting the urgent need to understand its underlying molecular mechanisms and identify potentially resistant patients for effective management. In this study, we constructed endocrine‐resistant cell lines through long‐term oestrogen deprivation and identified differentially expressed genes (DEGs) via transcriptome analysis. Key endocrine‐resistant genes were defined through Cox regression analysis. Our findings revealed that the genes CLEC3A, PCDH10, and ST3GAL1 were significantly upregulated in endocrine‐resistant cells and serve as independent prognostic factors for ER+HER2− BC patients. We developed an endocrine resistance score (ERS), and a nomogram model incorporating ERS demonstrated robust predictive capabilities for patient prognosis. Single‐cell RNA sequencing analysis demonstrated that the ERS and the three core genes constituting the ERS were significantly upregulated in tissue specimens from patients with resistance to endocrine neoadjuvant therapy. Additionally, knocking down CLEC3A, PCDH10, and ST3GAL1 led to reduced malignancy progression in endocrine‐resistant BC cells. Mechanistic studies revealed that CLEC3A promotes endocrine resistance by upregulating the PI3K‐AKT pathway. This study suggests that CLEC3A, PCDH10, and ST3GAL1 are associated with endocrine resistance and can reflect the prognosis of ER+HER2− BC patients receiving endocrine therapy, providing potential therapeutic targets and a valuable prognostic indicator for clinicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.
- The First People's Hospital of Foshan (The Affiliated Foshan Hospital of Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, China.
- The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong,…
ORCID-Profile: Hailin Tang, Kaiming Zhang
Zitieren
APA
Ping, L., Zhu, L., Chen, N., Liu, X., Zhong, J., Sun, X., Tang, H., & Zhang, K. (2026). Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER + HER2 − Breast Cancer. Cell Proliferation. https://doi.org/10.1111/cpr.70100
Vancouver
Ping L, Zhu L, Chen N, Liu X, Zhong J, Sun X, et al. Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER + HER2 − Breast Cancer. Cell Proliferation. 2026. doi:10.1111/cpr.70100
BibTeX
@article{Ping2026,
author = {Ping, Liqin and Zhu, Lewei and Chen, Nian and Liu, Xikun and Zhong, Jirui and Sun, Xiaoqing and Tang, Hailin and Zhang, Kaiming},
title = {Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER + HER2 − Breast Cancer},
journal = {Cell Proliferation},
year = {2026},
doi = {10.1111/cpr.70100}
}
EUVIMED